This segment brings together two essential threads — the broader context of lorlatinib's remarkable durability relative to ...

This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable ...

Kutscher says MDVIP is expanding into specialty care and eyeing pediatrics. Your browser does not support the audio element.

Positive symptoms correlated with more negative sentiment and longer utterances, whereas negative symptoms aligned with ...

FDA approved veligrotug-vvze for TED regardless of activity or duration, using a 12-week course of five IV infusions administered every three weeks. Pivotal THRIVE/THRIVE-2 trials met primary and all ...

Zanubrutinib plus rituximab demonstrated a clinically meaningful progression-free survival advantage over bendamustine plus rituximab in previously untreated MCL, with a 43% risk reduction for ...

In SYNCHRONIZE-MASLD (n=218), 84.2% on weekly survodutide 6.0 mg achieved ≥30% relative liver fat reduction versus 24.3% with placebo at week 48. Liver fat normalization occurred in ~61% of ...

Addressing social determinants of health is now a strategic pillar of organizational planning, compliance, and long-term sustainability. Social determinants of health (SDOH) — the conditions in which ...

Sponsored by Esperion. Newsletter Get the latest industry news, event updates and more from Managed Healthcare Executive.

Financial sustainability and innovation are interdependent, as clinician-led contracting strategies that improve outcomes generate savings that fund further innovation. Balancing innovation and ...

Reconstructed IPD meta-analysis showed chemoimmunotherapy improved OS and PFS versus PD-(L)1 monotherapy within PD-L1–high disease, with consistent findings across multiple analytic approaches and ...